BASEL, Switzerland (Reuters) – Swiss healthcare group Novartis said on Monday that early positive data in tests of Glivec have led to major protocol changes whereby some of the mirror test patients will also be given its cancer drug.
It said that in an interim analysis of a phase III study that compared Glivec to the standard therapy of interferon injections plus Ara-C chemotherapy for newly diagnosed chronic myeloid leukaemia (CLM) patients, Glivec was found to show a substantially higher response.
As a consequence, the Independent Data Monitoring Board recommended a change in the protocol to enable patients on standard therapy who have not achieved a major cytogenic response to switch to Glivec at this time.
Glivec is sold as Gleevec in the US
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!